Therabron Management Team:

Mr. Vinzenz Ploerer, M.B.A., Interim Chief Executive Officer

Mr. Ploerer is currently the interim Chief Executive Officer and also serves as Chairman on Therabron Therapeutics’ Board of Directors and as President and CEO of Brace Pharma Capital. In addition, Mr. Ploerer is a member of several other boards. A life science executive, Mr. Ploerer has multicultural experience in Asia, Europe, Latin America and the U.S., with expertise in general management, business development and strategic planning. His background also includes experience in identification of acquisition targets, negotiation, diligence and post-closing integration and transition, as well as business development and licensing in the pharmaceutical industry, including strategy portfolio planning. Mr. Ploerer holds an M.B.A. in Strategy from Leopold-Franzens Universität Innsbruck and participated in Novartis Leadership Program at Harvard Business School. He attended the Advance Management Program at Insead Fontainbleau.

Aprile Pilon, Ph.D. – Founder, Executive Vice President and Chief Scientific Officer

Dr. Pilon is a multi-functional executive with 22 years of broad-based entrepreneurial experience in the biopharmaceutical industry, including project management, fundraising, team building, corporate governance, licensing and IP strategy, regulatory submissions, clinical trial management, and business development. She is also an accomplished scientist, an inventor on over a dozen issued patents and several pending patents, and a principal investigator on several large USG grants. Dr. Pilon is Therabron’s founder and also a member of the Company’s board of directors.

Dr. Pilon holds a B.A. in Physics from Wheaton College and a Ph.D. in Molecular and Cell Biology from the Pennsylvania State University. She trained as a post-doctoral fellow at the National Institutes of Health before joining the biotech industry in 1992.

Board of Directors

Vinzenz Ploerer, M.B.A – Chairman

Serves as Chairman on Therabron Therapeutics’ Board of Directors and as President and CEO of Brace Pharma Capital. In addition, Mr. Ploerer is a member of several boards. A life science executive, Mr. Ploerer has multicultural experience in Asia, Europe, Latin America and the U.S., with expertise in general management, business development and strategic planning. His background also includes experience in identification of acquisition targets, negotiation, diligence and post-closing integration and transition, as well as business development and licensing in the pharmaceutical industry, including strategy portfolio planning. Mr. Ploerer holds an M.B.A. in Strategy from Leopold-Franzens Universität Innsbruck and participated in Novartis Leadership Program at Harvard Business School. He attended the Advance Management Program at Insead Fontainbleau.

Todd Brady

Todd Brady currently serves as the Director of Finance and Investments at Brace Pharma Capital. Mr. Brady also serves as a director for Brace portfolio companies GeNO LLC and Tyrogenex, as well as a board observer for Avidity Nanomedicines and Miragen Therapeutics. Mr. Brady has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. Mr. Brady has a Masters of Business Administration from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA).

Blanche M. Johnson, Ph.D.

Serves both as a Director and as Secretary of the Corporation. She is a consultant who provides business development and investment advisory services for clients that are developing products for, or investing in, the biomedical/life sciences industry. Her client list includes both public and privately held companies in the U.S. and Europe, and a venture capital fund based in Maryland. From October 2003 to March 2006, Dr. Johnson was an Entrepreneur in Residence at Johns Hopkins University working to create start-up companies based on intellectual property from Johns Hopkins. Prior to her work at Johns Hopkins, she ran Maryland Heath Care Product Development Corporation for nine years, a venture capital fund specializing in early-stage biomedical deals. She served as its Executive Director for two years and became President and a Director of the fund in 1997. Before her tenure with the fund, Dr. Johnson had a twelve-year career in product and marketing management in the research, health care and food safety testing markets with BioWhittaker, Environmental Diagnostics, and KPL; and, was the Vice President of a joint venture of Rhone-Poulenc called Diagnostix. She was educated as a Biologist (B.S. and M.S.) at the University of Illinois, Urbana, and received her Ph.D. from the Department of Biological Sciences at the University of Pittsburgh, where she trained as a biochemist. She was a post-doctoral fellow at the University of Pittsburgh Medical School, Department of Microbiology, studying cell biology. She has published three papers and numerous abstracts. Dr. Johnson’s Ph.D. thesis results were published in the journal Nature.

Aprile Pilon, Ph.D. – Founder, Executive Vice President and Chief Scientific Officer

In addition to Therabron Therapeutics, she founded three other biotechnology companies and served in management positions in all three. She has been a Director in two companies, one of which was VC-owned, over a 18-year period. In one of these companies, Claragen, she served as Secretary of the Corporation for several years. In addition to Therabron Therapeutics, she also currently serves as Chairperson for the Neonatal Drug Development Foundation, a non-profit dedicated to promoting clinical research in infants and young children.

Dr. Pilon is also an accomplished scientist, inventor, project/program manager, and principal investigator on Federal and local grant awards totaling over $3M. Dr. Pilon is the world’s leading expert on the CC10 drug candidate. She is a graduate of Wheaton College (Norton, MA; B.S. in Physics) and The Pennsylvania State University (Ph.D. in Molecular and Cell Biology).

Eric I. Richman

Mr. Richman has extensive experience in the development and commercialization of novel biotechnology-based therapeutics, most recently as President and Chief Executive Officer of PharmAthene, Inc., a NYSE-listed development-stage company, where he remains on the board of directors. Previously, Mr. Richman was part of the founding team at MedImmune, Inc. where he was responsible for the U.S. launch of MedImmune’s first commercial product, CytoGam®, and was an integral part of the global launch teams for marketed products including Synagis®, which generated peak annual sales over $1 billion. He was Chair of the Commercialization Committee as a director of LEV Pharmaceuticals, which launched the first HAE (Hereditary Angioedema) drug in the United States, until its acquisition by ViroPharma, Inc. Prior to joining MedImmune, he began his career at HealthCare Ventures, a life-sciences focused venture capital firm investing in pre-clinical or early clinical stage companies with potential to transform patient care. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a Masters of Business Administration from the American Graduate School of International Management. Mr. Richman currently serves on the board of directors of PharmAthene, Inc. and ADMA Biologics, Inc.

Jeffrey M. Zell

Serves as a Director on Therabron Therapeutics’ Board of Directors. Mr. Zell has over 30 years of experience managing facilities and logistics for expansions and contractions in the biotech and pharmaceutical industry. He is the President and Chairman of JM Zell Partners, Ltd., a real estate consulting, development and brokerage firm, based in Washington, D.C. JM Zell Partners supports some of the largest biotech and pharmaceutical company clients in North America. The U.S. Federal Court System has designated Mr. Zell as an expert in approximately 20 real estate industry areas. Mr. Zell is also a venture capitalist and the Managing Member of the Zell Biotech Funds. Mr. Zell is currently a member of the Syracuse Whitman School of Management Advisory Council and the National Geographic International Council of Advisors, and is a former President and board member of the Starlight Children’s Foundation. He received his B.S. degree from Syracuse University.

Scientific Advisory Board

Dr. Mario Castro, MPH, FCCP

Dr. Castro is Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine, and Professor, Medicine and Pediatrics, Division of Pulmonary and Critical Care Medicine at the Washington University School of Medicine in St. Louis, MO. He is affiliated with Barnes-Jewish Hospital in St. Louis and received his medical degree from the University of Missouri – Kansas City School of Medicine. He completed his fellowship in pulmonary/critical care, and his residency in Internal Medicine, at the Mayo Clinic and earned a graduate degree in Public Health from St. Louis University School of Public Health.

Dr. Gerard J. Criner

Dr. Criner, Chair and Professor of Thoracic Medicine and Surgery at Temple University School of Medicine. He is recognized as a worldwide expert on chronic obstructive pulmonary disease (COPD) and the management of intensive-care unit patients. Dr. Criner earned his medical degree from Temple University School of Medicine, where he also completed his residency. He completed a fellowship at Boston University School of Medicine and was on faculty at the University of Maryland.

Dr. Steven M. Donn

Dr. Donn serves as Professor of Pediatrics at C.S. Mott Children’s Hospital, part of the University of Michigan Health System, and is internationally known for his expertise in the management of respiratory failure in newborns. He obtained his medical degree from Tulane University, and undertook training in general pediatrics at the University of Vermont-Medical Center Hospital of Vermont and his fellowship training in Neonatal-Perinatal Medicine at the University of Michigan, where he is still actively involved in teaching, research and patient care activities.

Dr. Martin R. Zamora

Dr. Zamora is Professor of Medicine and Medical Director Lung Transplant Program, Pulmonary Sciences and Critical Care Medicine at the University of Colorado Denver – Anschutz Medical Campus in Aurora, CO. Dr. Zamora received his medical degree from the University of Colorado Medical School, where he also completed his internship, residency and fellowship training. He is Board Certified in Critical Care, Internal and Pulmonary Medicine.